CN114401741A - 干扰胸腺基质淋巴细胞生成素(tslp)受体信号传导的药剂 - Google Patents

干扰胸腺基质淋巴细胞生成素(tslp)受体信号传导的药剂 Download PDF

Info

Publication number
CN114401741A
CN114401741A CN202080062753.9A CN202080062753A CN114401741A CN 114401741 A CN114401741 A CN 114401741A CN 202080062753 A CN202080062753 A CN 202080062753A CN 114401741 A CN114401741 A CN 114401741A
Authority
CN
China
Prior art keywords
antibody
tslp
ser
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080062753.9A
Other languages
English (en)
Chinese (zh)
Inventor
谭玉清
张镝
师丽华
冯文昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuowei Innovative Biotechnology Hong Kong Co ltd
Original Assignee
Tuowei Innovative Biotechnology Hong Kong Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuowei Innovative Biotechnology Hong Kong Co ltd filed Critical Tuowei Innovative Biotechnology Hong Kong Co ltd
Publication of CN114401741A publication Critical patent/CN114401741A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080062753.9A 2019-07-11 2020-07-10 干扰胸腺基质淋巴细胞生成素(tslp)受体信号传导的药剂 Pending CN114401741A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962873051P 2019-07-11 2019-07-11
US62/873,051 2019-07-11
PCT/US2020/041642 WO2021007533A1 (en) 2019-07-11 2020-07-10 Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling

Publications (1)

Publication Number Publication Date
CN114401741A true CN114401741A (zh) 2022-04-26

Family

ID=74114844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080062753.9A Pending CN114401741A (zh) 2019-07-11 2020-07-10 干扰胸腺基质淋巴细胞生成素(tslp)受体信号传导的药剂

Country Status (8)

Country Link
US (1) US12435131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3996747A4 (cg-RX-API-DMAC7.html)
JP (1) JP7597784B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220033504A (cg-RX-API-DMAC7.html)
CN (1) CN114401741A (cg-RX-API-DMAC7.html)
AU (1) AU2020311432A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147044A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021007533A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025214333A1 (zh) * 2024-04-08 2025-10-16 江苏恒瑞医药股份有限公司 抗tslp抗体治疗与tslp相关的炎症疾病的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166739A1 (en) * 2021-02-04 2022-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CA3244178A1 (en) * 2021-12-24 2023-06-29 Inmagene Pte. Ltd. NEW ANTI-TSLP ANTIBODY
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
IL323448A (en) * 2023-02-23 2025-12-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Monoclonal antibody preparation targeting tslp
CN121443639A (zh) * 2023-06-22 2026-01-30 派拉冈医疗公司 结合tslp和tslpr的抗体及其使用方法
WO2025195445A1 (zh) * 2024-03-21 2025-09-25 北京三诺佳邑生物技术有限责任公司 特异性结合light和tslp的多特异性抗体以及组合物及其应用
CN120721972A (zh) * 2024-03-27 2025-09-30 北京智仁美博生物科技有限公司 鉴定抗人tslp双特异性抗体的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
CN1360596A (zh) 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
KR102731863B1 (ko) * 2014-03-27 2024-11-19 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法
US9535074B2 (en) 2014-09-08 2017-01-03 Merck Sharp & Dohme Corp. Immunoassay for soluble PD-L1
JP2018080114A (ja) 2015-05-29 2018-05-24 株式会社アールテック・ウエノ 抗ヒトvap−1モノクローナル抗体
MX2017016502A (es) * 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
EP3609917A1 (en) 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
US11396538B2 (en) 2017-12-20 2022-07-26 Radimmune Therapeutics, Inc. Antibodies to centrin-1, methods of making, and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025214333A1 (zh) * 2024-04-08 2025-10-16 江苏恒瑞医药股份有限公司 抗tslp抗体治疗与tslp相关的炎症疾病的方法

Also Published As

Publication number Publication date
JP2022540620A (ja) 2022-09-16
WO2021007533A1 (en) 2021-01-14
KR20220033504A (ko) 2022-03-16
EP3996747A1 (en) 2022-05-18
US20220251186A1 (en) 2022-08-11
US12435131B2 (en) 2025-10-07
EP3996747A4 (en) 2023-08-16
CA3147044A1 (en) 2021-01-14
AU2020311432A1 (en) 2022-02-03
JP7597784B2 (ja) 2024-12-10

Similar Documents

Publication Publication Date Title
US12435131B2 (en) Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
CN114729037A (zh) 抗tslp抗体及其用途
TW201922791A (zh) 雙特異性2+1康特斯體(Contorsbody)
JP2017511139A (ja) 多重特異性抗体
AU2019337394B2 (en) Improved anti-FLT3 antigen binding proteins
KR20180089514A (ko) Tnf-알파, il-17a 및 il-17f에 대해 특이성을 갖는 다중특이적 항체 분자
JP7834654B2 (ja) St2抗原結合タンパク質
TW202448940A (zh) 結合介白素4受體α之抗體及其使用方法
TW201039847A (en) Antibodies against human tweak and uses thereof
JP2026001077A (ja) Il-13及びil-18を標的とする多重特異的抗体
JP2025026957A (ja) IL-1β受容体シグナル伝達に干渉する剤
US10689452B2 (en) Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof
JP2022540846A (ja) Tnf-アルファおよびil-1ベータに対する二特異性抗体ならびにその使用
RU2841164C2 (ru) Белок, связывающий антиген st2
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
WO2024107731A2 (en) Anti-pd-l1 antibodies
JP2024541982A (ja) 新規の抗il-36r抗体
CN122003439A (zh) 抗IL-4Rα抗体及其用途
HK40078042A (en) Anti-tslp antibody and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination